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COCRYSTALS OF NURACEUTICALS: PROTOCATECHUIC ACID AND
QUERCETIN
Twarita Anil Pujari
ABSTRACT
The cocrystallization of two or more pure compounds by crystal engineering to
create a new functional material is of a great academic and industrial interest.
Pharmaceutical cocrystallization has allured a lot of attention by means of altering the
physicochemical properties of Active Pharmaceutical Ingredient (API) such as solubility,
stability and bioavailability. Crystal engineering of nutraceuticals can produce novel
compounds such as pharmaceutical cocrystals. To establish the importance of
nutraceutical cocrystallization and its use; polyphenols, a major class of nutraceuticals
and potential disease preventing agents, are the appropriate targets.
The work herein focuses on two polyphenols, protocatechuic acid and quercetin,
which are strong antioxidants. The cocrystals of quercetin have been synthesized, aiming
to modify its poor water solubility and bioavailability which limits its usage. On the other
hand, cocrystals of water soluble protocatechuic acid are also prepared to establish its use
as a cocrystal former. Seven novel cocrystals of protocatechuic acid and two novel
cocrystals of quercetin are obtained and are characterized by FTIR, DSC (Differential
Scanning Calorimetry), PXRD (Powder X-Ray Diffraction), single crystal x-ray
diffraction and TGA (Thermo Gravimetric Analysis). The new crystal forms have also
been studied via dissolution. Dissolution studies show alteration in solubility of a target
molecule by its cocrystal irrespective of solubility of the cocrystal former. Overall, the
study helps in understanding the role of crystal engineering and its utility.
ix

1. INTRODUCTION
1.1 Nutraceutical
Nutraceutical is the term used to describe a medicinal or nutritional component
which is present in food, plant or any naturally occurring material and which is used for
improvement of health by preventing or treating a disease.1 Nutraceuticals overlap with
the other health products such as pharmaceuticals and herbals.1 The complex relationship
is shown in Figure 1.1.

Figure 1.1 Relationship between nutraceuticals and other health products
Pharmaceuticals are usually classed as medicines by law however nutraceuticals
are available over the counter.2 Dr. Stephen De Felice, founder and chairman of the
Foundation for Innovation in Medicine (FIM, USA), first coined the term Nutraceuticals
in 1976.3 He defined it as a food, or parts of food, that provide medical or health
benefits, including the prevention and treatment of disease.1 The broad usage includes
supplementation for poor diet, to improve overall health, to delay the onset of age-related
diseases, for stress, after illness etc.1 However dietary supplements in the US can be
1

marketed without FDA approval. Thus Foundation for the Innovation in Medicine (FIM)
introduced the Nutraceutical Research and Education Act in Congress in October 1999. 1
It helped nutraceuticals to establish a new legal classification.4 Nutraceuticals are
popularly available in forms of tablets, capsules, softgels, soft chews etc.1
An American survey of consumer preferences for different formulations, carried
out in 2004 reveals that new drug delivery systems such as chewing gums and patches are
overcoming the traditional forms such as capsules.5 Nutraceuticals includes wide range of
products such as polyphenols (Epigallocatechin gallate (EGCG) from tea or resveratrol
from red grapes), vitamins, oils from fish and flax, calcium fortified juices, theobromine
from cacao tree, caffeine from coffee leaves etc.1

1.2 Crystal Engineering
A crystal, solid material, in which molecules are arranged in an orderly repeating
pattern extending in all three spatial dimensions, is an ultimate case of molecular
recognition. A series of complex molecular recognition with high level of precision
describes crystal as “supermolecules par excellence”.6 The rational design of new
crystalline materials led to the development of new field of crystal engineering.7 In 1955,
R. Pepinsky first coined the term crystal engineering who crystallized organic ions with
metal containing complexes.8 Subsequently in 1971, G.M.J. Schmidt implemented it in
the photodimerization of cinnamic acid.9 A working definition of crystal engineering was
given by Dr. Desiraju in 1989 , “crystal engineering is the understanding of
intermolecular interactions in the context of crystal packing and in the utilization of such
understanding in the design of new solids with desired physical and chemical
properties.”10 Crystal engineering has been explored vastly in different applications such
as non-linear optics (NLO) 11, porous materials,12 photographic materials13 and
coordination polymers.14 Pharmaceutical, one of the most significant sector, has started
utilizing the concept of crystal engineering very recently and it has been noted that crystal
engineering has a great impact on Active Pharmaceutical Ingredients (APIs). APIs are
among the most valuable crystalline substances and crystal engineering has been
successfully applied in the generation of cocrystals of APIs with improved
2

physicochemical properties.15,31

1.2.1 Supramolecular Chemistry
Supramolecular chemistry is referred as chemistry beyond the molecules.
Traditional chemistry focuses on covalent bond while supramolecular chemistry deals
with noncovalent interactions. In 1890 Nobel laureate Hermann Emil Fischer suggested
that enzyme-substrate interactions take the form of a "lock and key", pre-empting the
concepts of molecular recognition and host-guest chemistry. Gradually noncovalent
bonds were understood in more detail and the importance of supramolecular chemistry
was well established by 1987. Nobel Prize for chemistry was awarded to Donald J. Cram,
Jean-Marie Lehn and Charles J. Pedersen in recognition of their work in this area.17
Supramolecular chemistry has wide range of applications in different fields such as
material technology, catalysis, data storage and processing and green chemistry. Apart
from these; supramolecular chemistry has been used in the development of new
pharmaceutical therapies by understanding the interactions at a drug binding site.
Moreover it has a great impact on the studies of drug delivery and protein-protein
interactions.

1.2.2 Supramolecular Synthons
In 1967 E.J. Corey introduced a concept of a synthon18 as structural units within
molecules which can be formed and/or assembled by known or conceivable synthetic
operations. On the similar lines recognizing that crystal engineering is the solid-state
supramolecular equivalent of organic synthesis a term supramolecular synthon was
introduced by Dr. Desiraju in 1995.19 Supramolecular synthons are „structural units
within supermolecules which can be formed and/or assembled by known or conceivable
intermolecular interactions‟. Supramolecular synthons are spatial arrangements of
intermolecular interactions between complementary functional groups and simplifies
understanding of a crystal structure. Supramolecular synthons can be separated in two
distinct categories, Supramolecular homosynthons and supramolecular heterosynthons.
Supramolecular homosynthons are composed of identical self-complementary
3

functionalities20 such as carboxylic acid dimers21 (Figure 1.2 a) and amide dimers22.
Supramolecular heterosynthons are composed of different but complementary
functionalities such as carboxylic acid…amide23 and carboxylic acid…pyridine24 (Figure
1.2 b).

(a)

(b)

Figure 1.2: Examples of supramolecular (a) carboxylic acid homosynthon (b)
carboxylic acid···pyridine heterosynthon
1.2.3 Cocrystals
Cocrystals are a long known little studied class of compounds. The first entry of a
cocrystal was reported in 1844 by Wöhler; the cocrystal of benzoquinone and
hydroquinone (Refcode: QUIDON, Figure 1.3).25 Subsequently they were studied as
organic molecular compounds.26 However until 1960 the structural information on
cocrystals was absent and term complexes came in to the picture.

Figure 1.3: Crystal structure of the triclinic form of quinhydrone
In 1960‟s many people came up with different nucleic base complexes27 and the
term cocrystal was first used in this context.28 In 1963, K.Hoogsteen came up with the
new base pair known as “Hoogsteen base pair” which can be considered as the first
prototypal cocrystal. He studied the formation and properties of free radicals in a
4

cocrystal between 1-methylthyamine and 9-methyladenine (Refcode: MTHMAD Figure
1.4). Later the term cocrystal was subsequently popularized by Margaret Etter.29

Figure 1.4: The Hoogsteen base-pair
The definition of a cocrystal is still a topic of debate today.30 A broad definition of
a cocrystal was given by Dunitz; “a crystal containing two or more components
together.”31 In this view hydrates, solvates, inclusion compounds, clathrates can be
recognized as cocrystals. In Zaworotko research group and others, we have been using a
definition; “a cocrystal is a stoichiometric multiple component crystal in which all
components are solid under ambient conditions when in their pure form. These
components consist of a target molecule or ion and a molecular cocrystal former(s) and
when in a cocrystal they coexist at the molecular level within a single crystal.”32,33 This
definition distinguishes cocrystals from the other broad group of multiple component
compounds.
This emerging field of cocrystal allows modifying the composition of matter and
physicochemical properties of a molecule without breaking or forming a covalent bond.
Thus there are different applications for cocrystals. The most important field of
pharmaceutics is discussed in detail in section 1.4. Other relevant fields include solid
state synthesis and chiral resolution. In 1982 Etter et. al. reported a nucleophilic
substitution reaction, the first reaction in the context of solid state synthesis.34 Recently
Cheney et. al. have reported the condensation of amines and acid anhydrides synthesizing
imides.35
5

In 1848 Louis Pasteur reported spontaneous resolution of sodium ammonium
Tartrate.36 Generally racemates are known to be the result of 90% racemic mixtures.37
Chiral separation being a tedious process, the chiral cocrystal formers can offer an
enhanced possibility of separating enantiomers by fractional crystallization since the
resulting cocrystals are diastereomeric in nature. The well known example of chiral
separation is a spontaneous resolution of racemic mandelic acid by (s)-alanine and (R)cystine.38

1.2.4 Pharmaceutical Cocrystals
An attractive subset of cocrystals is pharmaceutical cocrystals. Pharmaceutical
cocrystals are defined as “cocrystals in which the target molecule or ion is an active
pharmaceutical ingredient, API, and it bonds to the cocrystal former(s) through
hydrogen bonds.”39

Figure 1.5: Representation of pharmaceutical cocrystal
Delivery of an API is generally preferred in a solid dosage form. API‟s are
developed in variety of solid forms and administered in different ways such as
amorphous, salt, polymorphs, solvates.40 The properties such as stability, solubility and
bioavailability of a drug are directed by its solid form. Thus it gives an opportunity to a
researcher to develop the best suitable form of a drug with improved physicochemical
properties.
First pharmaceutical cocrystal was reported in 1934 by Heyden et al. 41 He
patented cocrystals of Barbiturates with 4-oxy-5-nitropyridine, 2-ethoxy-5acetaminopyridine, N-methyl-alpha-pyridone and -aminopyridine. Complexes of a class

6

of -lactam antibiotics with parabens and related compounds were patented by Eli-Lilly
in 1995.42 Scientific literature database is getting enriched with number of
pharmaceutical cocrystals with improved physicochemical properties.
Carbamazepine: Saccharin 1:1 cocrystal (UNEZAO01) (Figure 1.6), developed
in 2003 by Almarsson and coworkers, was studied in vivo in dogs for their oral
pharmacokinetics. It showed the improved bioavailability than the marketed
carbamazepine drug, Tegretol®.43

Figure 1.6: 1:1 cocrystal of carbamazepine-saccarine
Sporanox® capsules containing itraconazole as an active ingredient used as an
antifungal agent and is extremely water insoluble. The aqueous dissolution of 2:1
cocrystal of itraconazole and succinic acid and other two cocrystals were studied in 0.1 N
HCl at 25°C which showed the improved dissolution profile (Figure 1.7).
Pharmacokinetic study of itraconazole cocrystals also revealed that cocrystal formulation
of the API gives similar oral bioavailability to the Sporanox® form in the animal trial
using a dog model.44

7

Figure 1.7: Dissolution profiles of Intraconazole and its cocrystals
Prozac®, an antidepressant drug, contains Fluoxetine hydrochloride as an API. In
2004, Childs et.al studied dissolution profile of the three cocrystals of fluoxine HCl in
water (Figure 1.8).45 Fluoxetine HCl: Succinic acid cocrystal showed two fold increase in
solubility as compared to fluoxetine HCl itself. It has also been observed that cocrystal
may decrease the solubility as in the case of fluoxetine HCl: benzoic acid.

Figure 1.8: Dissolution profile of fluoxetine HCl and its cocrystals
8

2-[4-(4-chloro-2-fluorophenoxy) phenyl] pyrimidine-4-carboxamide, a sodium
channel blocker (SCB), was developed for the treatment and prevention of surgical,
chronic and neuropathic pain. Many formulation trials failed to improve the
bioavailability of a drug. 1:1 cocrystal of a drug (SCB) with glutaric acid (Figure 1.9)
which was one of the hit from cocrystal screening showed physical and chemical stability
of a drug. Cocrystal increases in vitro rate of dissolution by 18 times when compared to
the pure API (Figure 1.10). Bioavailability studies on dogs confirmed that the cocrystal
improved the plasma AUC values by three times at both low (5 mg/kg) and high dose (50
mg/kg).46

Figure 1.9: Hydrogen bonding interactions between the carboxylic acid of the
glutaric acid molecule with the amide and pyridine groups of the drug molecule

Figure 1.10: Dog plasma concentration with time for (a) 5 mg/kg dosing and (b) 50
mg/kg dosing of a drug (dark circles) and cocrystal (open circles)

9

The cocrystal of Sildenafil citrate (active pharmaceutical ingredient in Viagra ®)
with aspirin was patented in 2007 which showed the improved solubility properties in
acidic conditions. Also it has shown the thermodynamic stability up to 1650C.47
Amgen developed a transient receptor potential vanilloid 1 antagonist, AMG 517,
for treatment of acute and chronic pain. The free base of AMG 517 is associated with
problems such as insolubility in water and buffers at physiological pH. Bak and
coworkers48 synthesized 10 cocrystals of AMG 517 and the physicochemical properties
such as particle size, solubility, stability, hygroscopicity, thermal behavior and structural
characteristics of these cocrystals were studied in detail. Further the solubility studies of
these cocrystals showed the increase in solubility and their conversion to AMG 517
hydrate.
In early 2007, pet food crisis, was observed in China. More than 24,000 clinical
assessments were found with acute renal failure within 3 months in Hong Kong. It was
observed that melamine, protein content in the pet food, forms a cocrystal with cyanuric
acid (QACSUI), another content of pet food. Even though melamine and cyanuric acid
are nontoxic individually the resulting 1:1 cocrystal (Figure 1.11) is highly insoluble in
water resulting in toxic kidney stones. It is a first example of cocrystals altering clinically
relevant physical properties in a negative manner.49

Figure 1.11: 1:1 cocrystal of melamine and cyanuric acid
Cocrystals or pharmaceutical cocrystals are novel as they can afford crystal
form diversity. The utility in terms of improving physicochemical properties of a drug
represents an opportunity to patent and market, clinically improved crystal forms of
available drugs in form of new drugs. In conclusion cocrystals and pharmaceutical
cocrystals are offering new avenues to the pharmaceutical industry.
10

1.2.5 Nutraceutical Cocrystals
As explained in 1.1 nutraceuticals are the naturally occuring nutritional products
that have health-related benefits and thus have an added advantage over pharmaceuticals.
Many nutraceuticals have a proven record in drug discovery such as aspirin and
penicillin. Nutraceuticals have established safety record and are readily available under
Good Manufacturing Practices (GMP). This will speed up the drug to clinic by lowering
the preclinical burden and toxicity risk. Even though nutraceuticals are the potential drug
candidates, many of them possess low water solubility and hence bioavailability.
Improving bioavailability by synthesizing a nutraceutical cocrystal has a large intellectual
property potential. On the other hand, highly water soluble, being safe, can serve as a
cocrystal former for a less soluble API to improve its solubility.

1.2.6 Synthesis of Cocrystals
A range of methodologies for the synthesis of cocrystals has been reported in the
literature. Single crystals are commonly developed via slow evaporation of a solution
containing stoichiometric amounts of target molecule and cocrystal former. The choice of
the solvent is crucial in obtaining a cocrystal since role of a solvent in nucleation of
crystals is poorly understood. Solid state grinding has been established from 19th century.
The very first cocrystal of quinone and hydroquinone was synthesized via grinding.25 The
technique of adding small amount of solvent i.e. solvent drop grinding or liquid assisted
grinding was shown to promote cocrystal formation.50 Automated grinding ballmills are
also developed for efficient synthesis. Another technique is the growth from melt in
which two components are placed together and melt is formed.51 The resulting solution is
seeded by remaining solid material and a cocrystal is formed. Slurry preparation,52
sublimation are the other suitable methodologies.

1.3 Solubility and Bioavailability
Solubility and bioavailability of a drug are important parameters in drug
development process. Intrinsic solubility and dissolution of a drug are prerequisites for
oral drug delivery. The fundamentals of the dissolution are studied by Noyes-Whitney
11

equation53 and the correlation of it with bioavailability leads to a Biopharmaceutics
Classification system (BCS).

1.3.1 Noyes-Whitney Equation
In 1897 the first dissolution experiment was performed by Noyes and Whitney for
benzoic acid and lead chloride.53The observations of this experiment was formulated in
terms of law which was expressed as, the rate at which a solid substance dissolves in its
own solution is proportional to the difference between the concentration of that solution
and concentration of the saturated solution. Its mathematical expression is as follows,

Where CS represents the solubility of the substance or the concentration of its saturated
solution; C the concentration at the expiration of time t and k a constant. Further with the
series of the experiment in 1900 Erich Brunner and Stanislaus von Tolloczko showed that
the rate of the dissolution depends on the exposed surface, the rate of the stirring,
temperature, structure of the surface and the arrangement of the apparatus.54 Thus
modified mathematical expression came out to be,

Where k1 is constant and S is the surface area. It implemented that the rate of dissolution
of a drug will increase if the bulk solubility will increase.55 In the period of 1950-1980
series of experiments showed that the rate of dissolution affects the bioavailability of
drug. And it is now well recognized that bioavailability gets influenced critically by
solubility.

1.3.2 BCS Classification
While understanding the complexity of the drug absorption process Amidon and
coworkers developed a simplified macroscopic approach and correlated drug absorption
and intestinal permeability.56 In addition, they developed a model for water insoluble
drugs. From these models it was well established that drug absorption is controlled by
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three factors; absorption number, dissolution number and dose number. All these
observations lead them to set a standard for drug bioavailability and Biopharmaceutics
Classification System (BCS) was proposed. According to BCS a substance is classified on
the basis of its aqueous solubility and intestinal permeability, and four drug classes were
defined i.e., high solubility/high permeability (Class I), low solubility/high permeability
(Class II), high solubility/low permeability (Class III), low solubility/low permeability
(Class IV) (Figure 1.12).
According to BCS a drug substance is considered highly soluble when the highest
strength is soluble in 250 ml or less of aqueous media over the pH range of 1.0–7.5;
otherwise, the drug substance is considered to be poorly soluble.57
BCS class II drugs present a challenge to cocrystallization field where cocrystals
can make a difference by altering the bulk solubility of a drug and hence altering the rate
of a dissolution and furthermore the bioavailability of an API. It has already been
demonstrated with cocrystals of carbamazepine, itraconazole and fluoxetine
hydrochloride as explained in section 1.2.4.

Figure 1.12: The Biopharmaceutics Classification System as defined by the FDA

1.4 Cocrystal Design
1.4.1 Cambridge Structural Database (CSD)
A prerequisite in cocrystal design is Cambridge Structural Database (CSD).
CSD is a database that was developed in 1965 at Cambridge University by Olga
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Kennard.58 CSD is a depository of X-ray and neutron diffraction data of organics,
organometallics and metal complexes containing up to 500 non-H atoms. The database is
a collection of bibliographic, information referencing the chemical connectivity in terms
of two dimensional (2D) structural formula and three dimensional (3D) molecular
structure and crystallographic data such as unit cell dimensions, space group, atomic
coordinate data (3D crystal structure).
CSD comprises of mainly four programs. ConQuest allows searching and
retrieving the information, Mercury for structure visualization, Vista gives numerical
analysis and PreQuest which is used for database creation. CSD database is rapidly
increasing and August 2008 release contains structural information of 456,628 organic,
metal-organic and organometallic crystal structures.
Designing a cocrystal first involves a CSD survey which helps in the
identification and understanding of supramolecular synthons of functional groups present
in target molecule. Analysis of intermolecular contacts facilitates the selection of a
cocrystal former.

Figure 1.13: Identification of supramolecular synthons using CSD

1.4.2 CSD statistics for Acids and Phenols
The chosen targeted molecules for the study contain phenol and acid
functionalities. Thus it is necessary to know about the statistics of existing synthons of
acid and phenol with other functional groups present in the CSD. All searches were
carried out by considering following constraints: no ions, only organics, R factor: ≤ 7.5%
and structures with 3D coordinates. The raw data includes any datasets with competing
hydrogen bonding functionality and refined data excludes the same.
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Figure 1.14: (a) Supramolecular OH OH homosynthon (b) Histogram of OH…O
hydrogen bond lengths in phenols
The CSD analysis reveals 7193 entries containing at least one phenolic OH
moiety. Phenols can form supramolecular homosynthon (Figure 1.14a). The raw search
contains 1028 (14.29%) entries that exhibit OH…OH supramolecular homosynthon. The
percentage of supramolecular homosynthon increases to around 59% when competing
functionalities are absent. Figure 1.14b shows the histogram for OH…O hydrogen bond.
The range of the hydrogen bond is 2.459-3.040 Å with the mean value of 2.809(2) Å. The
results are summarized in table 1.1.
There are 690 structures containing both phenolic OH and aromatic nitrogen base,
out of which 349 (50.58%) entries exhibit OH…Narom supramolecular heterosynthon
(Figure 1.15a) whereas 87 (12.60%) entries contain OH…OH supramolecular
homosynthon. When the competing hydrogen bonding groups are absent, there are 136
entries containing both phenolic OH and aromatic nitrogen base and out of these 38
(27.94%) shows OH…OH supramolecular homosynthon and 108 (79.41%) contain
OH…Narom supramolecular heterosynthon which explains the reliability of OH…Narom
synthon. The OH···Narom supramolecular heterosynthon occurs within the range 2.5153.066 Å (O···N) with an average O···N of 2.746() Å as shown (Figure 1.15b).
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Figure 1.15: (a) Supramolecular heterosynthon of phenolic OH…Narom
(b) Histogram of OH…Narom hydrogen bond lengths in phenols
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Figure 1.16: Supramolecular heterosynthons in phenol and primary amide
CSD holds 81structures containing both phenol and amide functionalities. Phenols
can hydrogen bond with amides in two different fashions. Raw data reveals that
supramolecular homosynthon of amide (30, 37.03%) dominates over the phenol… amide
supramolecular heterosynthon (Figure 1.16). Statistics obtained from refined data (3) is
too limited to generalize the hierarchy of these synthons.
The CSD analysis on phenols and carbonyl moiety was also carried out. It shows
the presence of 1668 structures. Supramolecular heterosynthon OH…O=C (Figure 1.17a)
is present in 599 (35.91%) entries whereas 212 (12.70%) entries contain the
supramolecular OH…OH homosynthon. The % of supramolecular heterosynthon
increases to 64% when competing groups are absent. The cut off range for OH…O=C is
2.413-3.038 Å with an average of 2.760(12) Å.
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Figure 1.17: (a) Supramolecular heterosynthon in phenol and carbonyl
moiety (aldehyde/ketone) (b) Histogram of OH…O=C hydrogen bond lengths
There are 363 entries containing both phenol and acid moieties. 90 (24.79%) of
them shows phenol-carbonyl OH…O=C supramolecular heterosynthon. The cut off range
for OH… O=C synthons is 2.613-3.039Å with the average value of 2.785(4) Å.

Figure 1.18: Histogram of OH…O=C and
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Table 1.1: Summary of the CSD statistics of phenols with other functionalities
CSD August 2008 release; Constrains: no ions, only organics, R factor: ≤ 7.5% and
structures with 3D coordinates
Functional
group present

No. of
structures

OH (Phenol)

7193

OH & Narom

690

OH &
primary
amide

81

OH & O=C

1668

OH &
carboxylic acid

363

Raw data
1028 (14.29%)
OH…OH
87 (12.60%)
OH…OH
349 (50.58%)
OH…Narom
30 (37.03%)
CONH2…CONH2
15 (18.52%)
OH…O=C(NH2)
21(25.92%)
OH…NH2
212 (12.70%)
OH…OH
599 (35.91%)
OH…O=C
70 (19.28%)
OH…OH
106 (29.20%)
COOH…COOH
90 (24.79%)
OH…O=C (acid)

No. of
structures
216

136

3

245

58

Refined data
127 (58.79%)
OH…OH
38 (27.94%)
OH…OH
108 (79.41%)
OH…Narom
1 (33.33%)
CONH2…CONH2
2 (66.67%)
OH…O=C(NH2)
3 (100%)
OH…NH2
53 (21.63%)
OH…OH
153 (62.45%)
OH…O=C
21 (%)
OH…OH
47 (%)
COOH…COOH
17 (29.31%)
OH…O=C (acid

Carboxylic acid is one of the important functional group in crystal engineering.
Carboxylic acid can act as both hydrogen bond donor as well as acceptor thus can form a
complementary unit with themselves. Two types of association are observed, dimers and
catemers (Figure 1.19).
The CSD data reveals 5943 entries which contain at least one carboxylic acid
functional group. The carboxylic acid dimer was observed in 1871 (31.48%) entries with
O…O range 2.50-3.00 Å with mean value of 2.650 (1) Å and catemers are observed in
176 (2.96%) entries. Whereas when other functionalities are absent, out of 683 entries
547 (80%) show acid dimers and 54 (7.9%) show acid catemers.
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Figure 1.19: Carboxylic acid dimers and catemers

Figure 1.20: Histogram of OH…O hydrogen bond lengths in carboxylic acid dimers
retrieved from CSD

19

Figure 1.21: (a) COOH…Narom supramolecular heterosynthon (b) Histograms of
OH…Narom hydrogen bond lengths in carboxylic acid-aromatic nitrogen bases
retrieved from CSD
Further analysis of CSD reveals 645 entries containing both carboxylic acid and
aromatic nitrogen base. The ability of carboxylic acids and aromatic nitrogen to form
reliable carboxylic acid-aromatic nitrogen supramolecular heterosynthon has been
already established.58 It shows 94.78% occurrence of COOH-Narom supramolecular
heterosynthon when other competing groups are not present. The cut off range for the
synthon is 2.50-3.045 Å with mean value of 2.652 (2) Å.

Figure 1.22: (a) COOH…O=C supramolecular heterosynthon (b) Histograms
of COOH…O=C hydrogen bond lengths in carboxylic acid with carbonyl
functionality
20

The analysis of carboxylic acid and carbonyl (aldehydes/ketones) reveals 621
entries with approximately similar occurrence of supramolecular heterosynthon and
supramolecular homosynthon. The occurrence of supramolecular heterosynthon increases
from 26 to 30% in case of refined data but supramolecular homosynthon dominates
(46.73%). The cut off range for COOH…O is 2.451-3.030 Å with mean value of 2.698(6)
Å.
The analysis of carboxylic acids and amides reveals that the COOH…CONH2
supramolecular heterosynthon shows 49.44% reliability of occurrence in the presence of
other competing groups whereas the percentage increases to 64.3% in the absence of
other hydrogen bonding functionalities. The total number of entries for the refined data is
limited to 28. The cut off range for NH2…O=C is 2.809-3.061 Å with mean value of
2.940(9) Å and for OH…O=C is 2.418-2.713 Å mean 2.564(5) Å.

Figure 1.23: (a) COOH…CONH2 supramolecular heterosynthon (b) Histograms of
NH2…O=C hydrogen bond lengths (c) Histograms of OH…O=C hydrogen bond
lengths in carboxylic acid with amide functionality
All above results for carboxylic acid are summarized in Table 1.2.
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Table 1.2: Summary of the CSD statistics for acids with other functionalities
Functional
group present

No. of
structures

COOH

5943

COOH & Narom

645

COOH &
primary
amide

178

COOH & O=C

621

Raw data
1871( 31.48%
dimers)
176 (2.96%
catemer)
COOH…COOH
32 (4.96%)
COOH…COOH
486 (75.35%)
COOH…Narom
8 (4.49%)
COOH…COOH
52 (29.21%)
CONH2…CONH2
88 (49.44%)
COOH…CONH2
158(25.44%)
COOH…COOH
164 (26.40%)
COOH…O=C

No. of
structures

683

134

28

199

Refined data
547( 80%
dimers)
54 (7.9%
catemer)
COOH…COOH
9 (6.7%)
COOH…COOH
127 (94.78%)
COOH…Narom
1
COOH…COOH
3
CONH2…CONH2
18 (64.3%)
COOH…CONH2
93 (46.73%)
COOH…COOH
78(39.20%)
COOH…O=C

Upon reviewing the CSD statistics obtained for phenols and acids, aromatic
nitrogen bases seem to be promising cocrystal formers. Also carbonyls, amides and
purines would be promising.

1.4.3 Cocrystal formers
A cocrystal former hydrogen bonds with the target molecule forming a cocrystal.
The data obtained from CSD statistics helps us to choose suitable cocrystal formers for a
target molecule. A cocrystal former must also be pharmaceutically acceptable or even
approved. Even though the capacity of available cocrystal formers is not fixed they are
limited to generally regarded as safe (GRAS) or a compound that has already been
approved by food and drug administration (FDA). Other characteristic features those are
taken in to an account are solubility, toxicity, pKa and cost. Tables 1.3, 1.4 and 1.5
summarize the cocrystal formers chosen for targeted molecules.
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Table 1.3: Cocrystal formers containing amide functionality

Structure

Mol. formula,
Name
Mol. Wt.
M.P (0C)

C6H11NO
Caprolactam
113.16
68-70

C6H10N2O2
Piracetam
142.16
153

C15H12N2O2
Oxcarbazepine
252.27
219-221

C15H12N2O
Carbazepine
236.37
203-205

Cost

pKa

LD50
mg/kg

Solubility
mg/ml

20.30/500
g

16.61
Acidic
-0.14
basic

1210
(Ratoral)

4560*
Soluble

47.40/25g

15.67
Acidic
-0.62
basic

12000
(Mousesubcutan
eous)

84
Soluble

65/10mg

13.73
basic
-0.53
acidic

4470
(rat,
oral)

0.35
Very
Slightly
soluble

41.70/5g

13.94 ±
0.20Acid
ic
-0.49 ±
0.20
basic

4025
(Ratoral)

0.078
Practically
Insoluble
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Table 1.4: Cocrystal formers containing purines

Structure

Mol. formula,
Name
Mol. Wt.
M.P (0C)
C7H8N4O2
Theobromine
180.16
357-358

C8H10N4O2
Caffeine
194.13
238
C5H5N5
Adenine
135.13
361

C7H8N4O2
Theophylline
180.16
271

Cost

pKa

LD50
mg/kg

Solubility
mg/ml

24.80/25g

9.90
basic
0.59acidi
c

300
(dog)

6.1
Slightly
soluble

57.70/250
g

0.73
basic

355
(Ratoral)

20
Slightly
Soluble

63.70/25g

10.43
basic

745
(Ratoral)

0.976
Very
Slightly
soluble

25.90/100
g

8.60±0.5
0
Acidic
1.45±0.7
0
basic

225
(Ratoral)

4.1
Slightly
soluble
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Table 1.5: Cocrystal formers containing aromatic nitrogen base

Structure
CH3

N
N

H3C

H
O

NH2
N

O

NH2

N

O

OH
N

O

OH

Mol. formula,
Name
Mol. Wt.
M.P (0C)
C5H8N2
3,5-dimethyl
pyrazole
96.13
105-108
C8H14N2O2
Isonicotinamid
e
122.12
155-157
C8H10N4O2
Nicotinamide
122.12
128-130

Cost

pKa

LD50
mg/kg

Solubility
mg/ml

49.20/100
g

15.2
basic
3.91acidi
c

1060
(mouse,
oral)

9
Slightly
soluble

39.40/100
g

14.96
acidic
3.39
basic

-

106*
Soluble

18.20/100
g

14.83
acidic
3.54
basic

1680
(Ratsubcutan
eous)

600*
Slightly
soluble

3123
(mouse,
oral)

16
Sparingly
soluble

5000
(rat,
subcutan
eous)

32
Sparingly
soluble

C6H4NO2
Isonicotinic
acid
123.11
>300
(decomposes)

13.30/50g

1.94
acidic
4.88
basic

C6H4NO2
Nicotinic acid
123.11
236-239

14.50/100
g

2.17
basic
4.82
acidic

N

* Practically determined values
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2. PROTOCATECHUIC ACID
2.1 Introduction
Protocatechuic acid (PA, Figure 2.1), (3,4- dihydroxybenzoic acid, C7H6O4, Mol.
Wt. 154.12, M.P. 2050C) is a phenolic acid1 in the broad class of polyphenols of the
nutraceuticals. It is widely available in oil, vegetables, fruits and tea. It is mainly found in
Roselle (Hibiscus sabdariffa) (Figure 2.2) which is a species of hibiscus found in old
world tropics.

Figure 2.1: Structure of Protocatechuic acid (PA)
PA is a strong antioxidant and in pharmaceutics it has been used as an
anticarcinogenic agent.2,3,4 PA is known for chemoprevention as well as tumor
progression. It induces apoptosis of human leukemia cells while on the other hand it
enhances tumor promotion in mouse skin cells.5 It has been predicted that higher dosage
of PA enhances tumor.6 The solubility of PA in water is 10mg/ml and LD50 is 800mg/kg
which makes PA a potential cocrystal former. PA (Figure 2.1) contains two phenolic
groups and a carboxylic acid group. Both can serve as hydrogen bond donor/acceptor.
Based on the CSD search, occurrence of supramolecular heterosynthons between
polyphenols with amides, basic nitrogen and purines would be promising in the context
of cocrystals. Thus different cocrystal formers containing such functionality were
selected on the basis of their solubility, toxicity, pKa and cost as summarized in tables
1.3, 1.4 and 1.5. The study herein focuses to establish the use of PA as a cocrystal former
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to improve the physicochemical properties of the target molecules.

Figure 2.2: A popular Roselle variety

2.1.1 Protocatechuic acid in CSD
The CSD analysis on PA revealed that the crystal structure of pure PA is not
known however there are three polymorphs (four entries) of PA monohydrate (Refcodes:
BIJDON, BIJDON1, BIJDON2 and BIJDON3) and an entry of PA acetonitrile solvate
(EDUWUW). Figure 2.3 represents the crystal packing of monohydrate of PA for ref
code BIJDON3. The coordinates for BIJDON, BIJDON1 and BIJDON2 are not available.
(a)

(b)

Figure 2.3: Hydrogen bonding in Protocatechuic acid monohydrate
The crystal structure of monohydrate of PA (BIJDON3) reveals that PA forms a
noncentrosymmetric carboxylic acid dimer; a supramolecular homosynthon (Figure 2.3 a)
(O…O: 2.717 Å and 2.592 Å) and these dimers form a chain through a water molecule.
Water molecules insert themselves between PA dimer chains forming a tetramer unit
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(Figure 2.3 b). Three phenolic OH groups (two from the same PA molecule and a third
from other PA molecule) are hydrogen bonded to water molecule and one water molecule
is hydrogen bonded to three molecules of PA.

Figure 2.4: Hydrogen bonding in Protocatechuic acid acetonitrile solvate
In the crystal structure of the acetonitrile solvate of PA, PA forms a carboxylic
acid dimer (O…O: 2.606 Å). One of the phenolic OH groups of PA is bonded to a
phenolic OH of another pair of a PA dimer (OH…O: 2.688 Å) to form a zig zag chain. An
acetonitrile molecule is trapped in between these chains via hydrogen bonding between
nitrogen atom of acetonitrile molecule and phenol moieties of PA (OH…N: 2.819 Å)
(Figure 2.4).

2.2 Cocrystals of Protocatechuic acid
Seven novel cocrystals of PA with ε-Caprolactam, Isonicotinamide, Isonicotinic
acid (hydrated and anhydrated cocrystals), Theophylline, Nicotinamide and
Carbamazepine are obtained. As discussed in section 2.1, carboxylic acid moiety and
phenolic OH groups of PA are likely to form hydrogen bonds. These functional groups
were used to form cocrystals with ε-caprolactam, isonicotinamide, isonicotinic acid,
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theophylline, carbamazepine and nicotinamide. The summary of cocrystals synthesized is
listed in table 2.1

2.2.1 Experimental Section
All chemicals were obtained from commercial sources and used without further
purification. Solvents were also purchased from commercial sources and distilled before
use. Single crystals of cocrystals 1 to 3 and 5 to 7 were obtained by slow evaporation of
stoichiometric amounts of starting materials in an appropriate solvent as summarized in
table 2.2 and they were removed from their mother liquors before complete evaporation
of the solvent. Samples were characterized by powder X-ray diffraction, infrared
spectroscopy differential scanning calorimetry, thermo gravimetric analysis (for cocrystal
3) and single crystal X-ray data was collected for cocrystals 1-3 and 5-7.
Table 2.1: Summary of the cocrystals of PA synthesized
Cocrystal

Target molecule

1

ε-Caprolactam

2

Isonicotinamide

3

Isonicotinic acid

4

Isonicotinic acid

5

Theophylline

6

Nicotinamide

7

Carbamazepine

Structure
and Ratio
Anhydrous
(1:1)
Anhydrous
(1:1)
Monohydrate
(1:1:1)
Anhydrous
(1:1:1)
Anhydrous
(1:1)
Anhydrous
(1:1)
Anhydrous
(1:1)

Melting Point
(0C)

Yield
(%)

131

95.4

195

65.9

224

62.5

223

-

254

49.5

201

28.4

-

89.2

2.2.2 Cocrystallization via Solution Crystallization
1:1 cocrystal of PA and ε-Caprolactam, 1:
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O

O

OH

NH

MeOH + Water
C7H6O4.C6H11NO
OH
OH

Figure 2.5: Synthesis and single crystal of 1
PA (15.4 mg, 0.0999mmol) and ε-caprolactam (11.3 mg, 0.0998mmol) were
dissolved in 1ml of methanol and 3ml of water by heating. The resulting solution was
allowed to stand at room temperature and slowly evaporate. Colorless crystals (25.5 mg,
0.0954 mmol, 95.5%) were harvested after 13 days and exhibited a melting point of
1310C.
1:1 cocrystal of PA and Isonicotinamide, 2:
O

OH
O

NH2

MeOH + Water
C7H6O4.C6H6N2O
OH
N
OH

Figure 2.6: Synthesis and single crystal of 2
PA (15.4 mg, 0.0999 mmol) and isonicotinamide (12.2 mg, 0.0998mmol) were
dissolved in a mixture of 1ml of methanol and 3ml of water by heating. The resulting
solution was allowed to slowly evaporate at room temperature. Colorless crystals of II
(18.2 mg, 0.0659 mmol, 65.9 %) were harvested after 8 days and exhibited a melting
point of 1950C.
Monohydrate of 1:1 PA and Isonicotinic acid, 3:

34

O

OH

OH

O

MeOH + H2O

+

C7H6O4.C6H5NO2.H2O

OH

N

OH

Figure 2.7: Synthesis and single crystal of 3
PA (15.4 mg, 0.0999mmol) and isonicotinic acid (12.3 mg, 0. 0999 mmol) were
dissolved in 5ml of 1:1 mixture of water and methanol by heating. The resulting solution
was placed at room temperature and allowed to slowly evaporate. The colorless needle
crystals (17.3, 0.0586 mmol, 62.5%) were harvested after 13 days and exhibited melting
point of 2240C.
Cocrystal of PA and Isonicotinic acid, 4:
Cocrystal of anhydrate of protocatechuic acid and isonicotinic acid was prepared
by dehydrating 3. Crystals of 3 were heated in an oven at 120oC for 48 hours thereby
affording cocrystal 4. Unfortunately the single crystal was not harvested. The cocrystal
exhibited a melting point of 2230C.
1:1 cocrystal of PA and Theophylline, 5:
O

OH

O

H

H3C

N

N

MeOH
C7H6O4.C7H8N4O2

O

N

N

OH
CH3
OH

Figure 2.8: Synthesis and single crystal of 5
PA (15.4 mg, 0.09mmol) and theophylline (18.0 mg, 0.09mmol) were dissolved
in a 4ml of methanol and the resulting solution was allowed to slowly evaporate at room
temperature. Colorless blocks of crystals of 5 (Figure 2.8) (16.5 mg, 0.0497 mmol,
49.5%) were harvested after 3 days and exhibited a melting point of 2540C.
1:1 cocrystal of PA and Nicotinamide, 6:
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O

OH

O

OH

water slurry
Methanol
C7H6O4.C6H5NO2
Slow evaporation
OH
N
OH

Figure 2.9: Synthesis of 6
PA (30.8 mg, 0.199mmol) and nicotinamide (24.4 mg, 0.199mmol) were slurried
in a 1ml of methanol for 2 hrs and the resulting mixture was dissolved in 1ml of water
and then allowed to slowly evaporate at room temperature. Colorless thin crystals of 6
(15.7mg, 0.0546 mmol, 28.4%) were harvested after 7 days and exhibited a melting point
of 2010C.
Dihydrate of 1:2 cocrystal of PA and Carbamazepine, 7:
O

OH

Water+Acetone
C7H6O4.C15H12N2O

N

or Methanol
NH2 Slow evaporation

OH

O

OH

Figure 2.10: Synthesis and single crystal of 7
PA (15.4 mg, 0.09mmol) and carbamazepine (18.0 mg, 0.09 mmol) were
dissolved in a 5ml of methanol and the resulting solution was allowed to slowly
evaporate at room temperature. Colorless crystals of 7 (29.7mg, 0.0264 mmol, 89.2%)
were harvested after 2 days. Crystals were also harvested by dissolving the starting
materials in same quantities by heating in a mixture of water (3ml) and acetone (1ml)
after 3 days.

2.2.3 Cocrystallization via Grinding and Slurry conversion
Attempts were made to synthesize the cocrystals using different methodologies
described in 1.2.6. For grinding starting materials were ground in a mortar and pestle
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using respective solvents and resulting powders were analyzed by X-ray powder
diffraction. Also Cocrystal 5 was synthesized using an automated grinder (Retseh
MM301 ball mill) for 90 min. The results from slurry and grinding are summarized in
table 2.2.
Table 2.2: Comparison of solvent evaporation, grinding and slurry techniques

1
2
3
5
6

Molar ratio
used
1:1
1:1
1:1
1:1
1:1

7

1:1

Cocrystal

Crystallization
solvent
MeOH/Water
MeOH/Water
MeOH/ Water
MeOH
MeOH
MeOH and
Water/Acetone

Solvent for
grinding
DMF
Water
Water

Solvent for
slurry
Water
Water
Water
Water

MeOH

-

2.2.4 FTIR, PXRD, Differential Scanning Calorimetry and Thermo
Gravimetric Analysis
All samples were characterized by IR spectroscopy using a Nicolet-Avatar Smart
Miracle 320 FT-IR instrument. The bulk samples were analyzed by X-ray powder
diffraction. PXRD analysis was performed using a Bruker D8 ADVANCE, θ /2 θ
diffractometer. Experimental conditions: Cu K radiation (λ= 1.54056 Å); 50 kV and 40
mA. Scanning interval: 3-400 2 θ; time per step: 0.5 s; step size: 0.020. Thermal analysis
was carried out using TA instrument DSC 2920 differential scanning calorimeter.
Aluminum pans were used for the experiment for all the samples. Temperature
calibrations were made using indium as the standard. An empty pan, sealed in the same
way as the sample, was used as a reference. The thermograms were run at a scanning of
100C/ min from 300C to the required temperature on 1-3mg of the sample.
Thermogravimetric analysis was carried out using STM6000. Results are summarized in
figures 2.11- 2.17.
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Figure 2.11: Cocrystal 1: (a) PXRD comparison (b) DSC (C) IR
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Figure 2.12: Cocrystal 2: (a) PXRD comparison (b) DSC (C) IR
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Figure 2.13: Cocrystal 3: (a) PXRD comparison (b) TGA (c) DSC (d) IR

1.8
1.6

Relative Intensity

1.4
1.2
1.0
0.8

cocrystal IV_experimental

0.6

cocrystal III_calculated

0.4

Protocatechuic acid H2O_calculated

0.2

Isonicotinic acid_calculated
Protocatechuic acid_experimental

0.0
0

5

10

15

20

25

2(a)
degree

(b)

43

30

35

40

45

(c)
Figure 2.14: Cocrystal 4: (a) PXRD comparison (b) DSC (c) IR
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Figure 2.15: Cocrystal 5: (a) PXRD comparison (b) DSC (c) IR
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Figure 2.16: Cocrystal 6: (a) PXRD comparison (b) DSC (c) IR
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Figure 2.17: Cocrystal 7: (a) PXRD comparison (b) TGA (c) IR (d) DSC (e) DSC
after heating cocrystal 7

2.2.5 Determination of Crystal Structure
Single crystals of cocrystals 1-3 and 5-7 were examined under a microscope and
single crystal X-ray diffraction data was collected on a Bruker-AXS SMART APEX
CCD diffractometer with monochromatized Mo K radiation (λ = 0.71073 Å) connected
to a KRYO-FLEX low temperature device.
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Table 2.3: Crystallographic data for cocrystals of PA
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2.2.6 Results and Discussion

Figure 2.18: Each PA molecule is hydrogen bonded to three molecules of εcaprolactam through phenol…carbonyl supramolecular heterosynthon
The crystal structure of 1 reveals that PA exists as carboxylic acid dimer [O…O:
2.659(3)Å] and dimers are further connected to ε-caprolactam molecules through
hydrogen bonding between the carbonyl moiety of PA and NH moiety of ε-caprolactam
[NH…O: 2.882(3)Å] forming a heterocatemer. Each PA molecule is connected to three
molecules of ε-caprolactam. Additional hydrogen bonding affords a three dimensional
network. These interactions help to establish the reported interactions.
ε-caprolactam is an organic molecule which has been listed on GRAS list. Two
polymorphs (Refcodes: CAPLAC and CAPLAC01 and eight cocrystals are reported in
CSD for caprolactam [Ref. codes: CAPRES (with 4-chlororesorcinol), KEWZUE (4,4'Biphenol), QQQGHM and QQQGHM01(with resorcinol), QQQGHP (with
hydroquinone), QQQGHS and QQQGHS01(with 5-methylresorcinol) and QQQGHV
(with -naphthol)]. The coordinates are not available for five of them (QQQGHM,
QQQGHP, QQQGHS, QQQGHS01, QQQGHV). In CAPRES and KEWZUE it can be
noted that ε-caprolactam exists as lactam dimer forming a supramolecular homosynhon
with CO…HN distances 2.901 Å, 3.014 Å respectively. While in the QQQGHM01, ε51

caprolactam in addition to the lactam dimer (CO…HN: 2.950 Å); supramolecular
heterosynthon within the phenolic moiety of resorcinol and lactam (CO…HO: 2.665 Å
and NH…O: 2.998 Å) has been also observed with lactam acting as both hydrogen bond
donor and acceptor to a phenolic OH moiety. In the case of 1, PA breaks the lactam
dimer forming a heterocatemer with supramolecular heterosynthon between carbonyl
moiety of carboxylic acid and phenolic group of PA having bond distances of NH…O:
2.882(3) Å and OH…O: 2.736(3) Å respectively.
Major peaks at 7.2, 9.1, 17.0, 21.1, 24.4, 25.5 and 28.0 degrees in experimental
powder patterns matches with calculated PXRD (Figure 2.11a). The DSC shows sharp
endotherm at 131.070C (Figure 2.11 b) which falls between the melting points of the two
starting materials (Protocatechic acid: 2050C Caprolactam: 680C).

Figure 2.19: Formation of a tape with alternate PA and isonicotinamide molecules
by acid…pyridine supramolecular heterosynthon
The single crystal X-ray structure of 2 reveals that isonicotinamide molecules
break the PA acid dimers and forms tapes through an acid…pyridine [COOH…Narom
(O…N: 2.669(10)Å)] and amide…phenol [N…O: 3.042(13)Å] supramolecular
heterosynthons. These tapes with alternate molecules of PA and isonicotinamide are
further connected to each other through carbonyl amide and carbonyl phenol
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supramolecular hetersynthons [N…O: 3.021(13) Å and O…O: 2.762(10) Å]. The C-N-C
angle of pyridine ring in isonicotinamide was observed to be 116.700.

Figure 2.20: One molecule of PA is hydrogen bonded to five molecules of
isonicotinamide
There are three entries for isonicotinamide with two polymorphs of it (EHOWIH,
EHOWIH01 and EHOWIH02) in CSD. Recently Seaton et. al. reported monohydrate of
isonicotinamide.19 Apart from this forty one cocrystals are reported till date in CSD.
[AJAKAX (with hex-2-enoic acid), AJAKEB (with 4-nitrobenzoic acid), AJAKIF (with
3,5-dinitrobenzoic acid and 4-methylbenzoic acid), ASAXOH (with 3-Nitrobenzoic
acid), ASAXUN (with 4-fluorobenzoic acid), BUDWEC (with benzoic acid), BUDZUV
(with 3,5-dinitrobenzoic acid and 3-methylbenzoic acid), BUFBIP (with 3,5Dinitrobenzoic acid and 4-(N,N-dimethylamino) benzoic acid), BUFQAU (with 3,5Dinitrobenzoic acid and 4-hydroxy-3-methoxycinnamic acid), JAWWEK (cis,cis-1,3,5Cyclohexanetricarboxylic acid), LUNMAI (with cinnamic acid), LUNMEM (3hydroxybenzoic acid), LUNMIQ (with 3-(N,N-dimethylamino) benzoic acid),
LUNMOW (with 3,5-bis (trifluoromethyl) benzoic acid), LUNMUC (with 12bromododecanoic acid), LUNNAJ (with monochloroacetic acid), LUNNEN (with
fumaric acid monoethyl ester), LUNNIR (with 4-ketopimelic acid), LUNNOX (with
fumaric acid), LUNNUD and LUNNUD01 (with succinic acid), LUNPAL (d,l-mandelic
acid), LUNPEP (with thiodiglycolic acid), MELYEI (with pyridine-2,6-dicarboxylic acid
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and water), ULAWAF (with Oxalic acid), ULAWEJ (with malonic acid), ULAWOT and
ULAXAG (with glutaric acid), ULAWUZ and ULAXEK (with adipic acid), VAKTOR
(4-hydroxybenzoic acid), VAKTUX (with resorcinol), VAKVEJ (with phloroglucinol
and water) , VAKVIN (with hydroquinone), VETVUM (with 1-Ethyl-6-fluoro-1,4dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and chloroform), XAQPOV
(with 3,5-dinitrobenzoic acid and 3,4-dimethoxycinnamic acid), XAQQEM (with 2hydroxybenzoic acid), ULAWAF01(with cis-oxalic acid), ULAWAF02 (with transoxalic acid), YIPCEG (with iodine) and YIPCIK (with p-tetrafluorodi-iodobenzene).
Among these structures 35 of them are with carboxylic acids. The crystal
structures of 34 form acid…pyridine supramolecular heterosynthon with exception of one
(VAKTOR) having carboxylic acid…amide and phenol…pyridine supramolecular
heterosynthons. In accordance with these observations as predicted this dominant acidpyridine supramolecular heterosynthon was observed in case of 2.
The C-N-C angle in aromatic nitrogen moieties are known to be sensitive to
protonation.7 Also the geometrical features of carboxylic acid and carboxylate are known
to be different.8 Thus examination of quantitative differences such as C-N-C angle of
pyridine to protonation at nitrogen and distinction in C…O bond lengths between
carboxylate and carboxylic acid will further provide an information whether 2 is a
cocrystal or a salt.9
If the proton transfer from a carboxylic acid to base i.e pyridyl nitrogen in the
case of 2, which lead to formation of a salt, takes place, the carboxylate ion shows the
same bond distance for C…O. In the case of cocrystal formation, bond lengths of C…O
and C…OH differ which is observed in 2; the distances are 1.222 Å and 1.323 Å.
From table 2.4 it has been observed that C-N-C angle in 41 cocrystals of
isonicotinamide with 35 carboxylic acids, 1 zwitterion, 3 phenols and 2 halogenated
molecules is in the range of 116.90 to 119.910. The C-N-C angle in 2 is 116.700 which
can be correlated with the observed range supporting the neutral nature of
isonicotinamide in the structure.
The difference in pKa of aromatic nitrogen base and carboxylic acid is used as an
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indicator to conclude whether it‟s a salt or neutral bond or proton transfer results. In
pharmaceutical industry pKa difference greater that 2 or 3 are used for salt formation.10
ΔpKa= pKa(base)-pKa(acid) for 2 is -1.06 which suggests the formation of neutral bond.
Hence in 2; pyridine nitrogen is not protonated giving rise to formation of neutral
cocrystal and not a salt. Solution NMR is also a useful technique to conclude whether it is
a salt or cocrystal.
PXRD comparison shows major peaks are present in the experimental powder xray diffraction pattern at 16.0, 18.1, 24.6, 25.7, 26.7, 29.3, 29.6 and 31.50 2 positions
match with the calculated powder pattern (Figure 2.12 a). Also powder pattern from
water slurry shows the formation of cocrystal. DSC shows a sharp endotherm at 195.290C
(Figure 2.12 b) which falls in between the melting points of starting materials (PA:
2050C; Isonicotinamide: 155-1570C).
Table 2.4: C-N-C angles in neutral isonicotinamide cocrystals from CSD

AJAKAX
AJAKEB
AJAKIF

C-N-C angle
(0)
117.60
118.63
117.68

LUNMUC
LUNNAJ
LUNNEN

C-N-C angle
(0)
117.16
119.15
118.19

117.29

LUNNIR

117.69

VAKTUX

ASAXUN

117.03

LUNNOX

118.24

VAKVEJ

BUDWEK
BUDZUV
BUFBIP

117.68
117.69
117.66

VAKVIN
VETVUM
XAQPOV

BUFQAU

118.46

LUNNUD
117.58
LUNNUD01 118.01
LUNPAL
117.46
117.46
LUNPEP
118.28

C-N-C
angle (0)
117.35
118.22
116.90
117.48
117.60
117.29
117.63
117.33
115.88
117.39

ASAXOH

XAQQEM

117.86

MELYEI

117.35

ULAWAF01

119.67

ULAWAF

119.47
118.62
119.02
119.37
119.48
120.58
117.38
117.55

ULAWAF02

119.91

ULAWUZ

118.05

LUNMOW

117.74

Refcode

Refcode

LUNMAI

116.86
117.35
117.86

LUNMEM

118.18

ULAWEJ

LUNMIQ

117.25

ULAWOT

JAWWEK
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Refcode
ULAXAG
ULAXEK
VAKTOR

Figure 2.21: PA molecules forming acid-acid supramolecular homosynthon
and supramolecular heterosynthons with two water molecules and one isonicotinic
acid molecule.
The single crystal X-ray analysis of 3 shows PA molecule exist as a carboxylic
acid dimer [O-H…O: 2.616(6) Å] and isonicotinic acid molecules exist as zwitterions.
One of the phenolic group of PA is hydrogen bonded to the isonicotinic acid through
water molecule [H2O…OH: 2.621(5) Å] and the remaining phenolic moiety is hydrogen
bonded to isonicotinic acid [O-H…O: 2.706(6) Å]. PA molecules forms dimers and
isonicotinic acid molecules form a chain hanging out to either side of protocatechuic acid
dimers (Figure 2.22). The zwitterionic nature of isonicotinic acid molecule is supported
by C-N-C angle of 121.500 in pyridine ring.

Figure 2.22: Formation of isonicotinic acid chains in 3
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An analysis of the CSD shows no cocrystals of isonicotinic acid. But the crystal
structure of neutral isonicotinic acid is known in CSD with ref. code ISNICA. Also there
are five entries involving isonicotinate ion. [AJECAT (with 3,5-dinitrosalicylate),
FETXIM (4-Aminopyridinium and water), REFFIS (with R-1,1'-binaphthalene-2,2'-diylphosphate), XECDUF and XECDUF01 (with chloride) and YERXUP (with 2,5dichloro-4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-olate and water)]. Based on these
observations Zaworotko et. al recently published that the COOH…Narom supramolecular
heterosynthon that would be expected if a cocrystal were to form.11 This expected
supramolecular synthon is present in cocrystal 3. Further whether 3 is a salt or a
zwitterionic cocrystal can be distinguished as explained in the case of 2; by the
examination of C-N-C angle and the location of proton by C…O distances in carboxylate
and carboxylic acid.
The C-N-C angle of 3 supports the non existence of neutral isonicotinic acid
molecule since the C-N-C angle in neutral isonicotinic acid is 118.910. The salt is an
ionic species whereas zwitterion is a species which carries a total net charge of zero but
carries formal positive and negative charges on different atoms within the molecule. In 3,
examination of bond lengths in carboxylic acid moiety (C…O: 1.224 Å and 1.259 Å)
resulted the presence of carboxylate ion. This carboxylate carrying formal negative
charge and pyridyl nitrogen of isonicotinic acid carrying a formal positive charge
because of a proton transfer gives rise to overall neutral molecule. Hence 3 is a
zwiterionic cocrystal.
The major peaks at 13.3, 17.3, 19.1, 22.9, 23.8, 25.2, 27.8 and 39.3o from the
experimental powder x-ray diffraction pattern (Figure 2.13 a) matches with the calculated
powder pattern. DSC shows three endotherms (Figure 2.13 c). The endotherm at
115.100C corresponds to solvent molecule which is a water molecule and endotherm at
224.200C corresponds to cocrystal of anhydrate. The third endotherm around 3000C may
correspond to the decomposition of isonicotinic acid. TGA (Figure 2.13 b) supports the
loss of water molecule (5.24%) which correlates the calculated % loss (6.09%).
Attempts to obtain single crystal of 4 were unsuccessful. But the powder X-ray
diffraction data after heating 3 shows the formation of new cocrystal (Figure 2.14 a)
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which is well supported by DSC. The absence of first endotherm from 3 shows the
absence of water molecule in the 4. Also endotherm at 223.190C correlates with the
endotherm present in 3.

Figure 2.23: Acid dimer of PA molecules forming supramolecular
heterosynthon with theophylline dimers
The single crystal X-ray crystallographic study analysis of 5 reveals that PA
forms a acid dimer [O-H---O: 2.636(19) Å] and theophylline form dimers with
N-H…O=C contacts at a distance of 2.781(2) Å. The two remaining phenolic groups form
PA hydrogen bonds with theophylline molecules through OH---O=C [2.703(17) Å] and
OH---N contacts [2.774(2) Å] to establish an overall sheet structure. Each PA molecule is
hydrogen bonded to two theophylline molecules through phenolic OH moieties (Figure
2.23).
Theophylline is a naturally occurring drug (present in tea) used in the treatment of
respiratory diseases such as asthma. The crystal structure of anhydrous and monohydrate
of theophylline as well as number of cocrystals have been reported to date in CSD
[Reference codes: CSATEO (with 5-chlorosalicylic acid); DUXZAX(with urea);
SULTHE (with sulfathiazole); THOPBA (with phenobarbital);TOPPNP (with pnitrophenol);WUYROX (with N-(2-aminoethyl)-carbamate); XEJWUF (with oxalic
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acid); XEJXAM (with malonic acid), XEJXEQ (with maleic acid); XEJXIU (with
glutaric acid); ZAYLOA (with 5-fluorouracil and water) and ZEXTIF (with pnitroaniline); KIGKAN (with citric acid and water); KIGLAO (with sorbic acid);
KIGLES (with salicylic acid); KIGLIW (with 1-hydroxy 2-napthoic acid); KIGLOC
(with 4-hydroxy benzoic acid); KIGLUI (with N-(4-hydroxyphenyl)acetamide);
XOBCUN (with saccharin)]. In theophylline there are three sites of hydrogen bond
acceptor and also one site of hydrogen bond donor. Out of 23 cocrystals 9 of them shows
theophylline dimers in the crystal structure. In 5 it can be observed that this dimer as well
as phenol…imidazole and phenol…carbonyl supramolecular heterosynthon is present.

Figure 2.24: Formation of sheets in 5
PXRD of experimental pattern shows major peaks at 11.6, 15.8, 22.8, 25.2 and
27.3o which are present in the calculated powder x-ray diffraction pattern (Figure 2.15 a).
The sharp endotherm in DSC (Figure 2.15 b) at 254.280C falls in between the melting
points of the starting materials (PA: 2050C; Theophylline: 2740C).
The single crystal X-ray studies of 6 reveals that PA and nicotinamide forms an
acid amide dimer [N…O: 2.875(18) Å and O…O: 2.639(17) Å]. One unit of dimer is
hydrogen bonded to other in helical fashion in which amide moiety is hydrogen bonded
to carbonyl moiety of PA [N…O: 2.990(2)Å]. Also aromatic pyridine nitrogen of
nicotinamide hydrogen bonds to phenolic OH of PA [Narom…O: 2.671(17) Å] to form the
helix. Dimer units in the helix create pi-pi stacking (centroid to centroid distance 3.750
Å). Nicotinamide is a small molecule of vitamin B family. Nicotinamide serves as a
target molecule because of its high medicinal value such as anti-anxiety,12 anti
inflammatory13 and in Alzheimer‟s disease.14 Two polymorphs of nicotinamide are
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known in CSD with three entries (Refcodes: NICOAM01, NICOAM02, NICOAM03).
There are eleven cocrystals of nicotinamide are reported in CSD till date. FIFLAI,
UCOTUC, VIGDAR, IACNCA, JEMDIP, PEQBES, UNEZES, XAQPUB, XAQQIQ,
CIPHAL, JILZOU.

Figure 2.25: One molecule of PA is hydrogen bonded to two molecules of PA
through OH…OH supramolecular homosynthon, one molecule of nicotinamide
through acid…amide supramolecular heterosynthon and with another nicotinamide
molecule through OH…NH2 supramolecular heterosynthon
Among 11 cocrystals; 8 of them are with carboxylic acid and in these 8 cocrystal
1 is phenolic acid. Except XAQQIQ in rest all 7 cocrystals carboxylic acid-pyridin
supramolecular heterosynthon was observed. XAQQIQ exhibits carboxylic acid-primary
amide and phenol-pyridine supramolecular heterosynthon. This was expected in the case
of 6 and observed the same. The C-N-C angle for nicotinamide cocrystals are
summarized in table 2.5, which shows the range of 116.81 to 118.25. In case of 6 the
observed C-N-C angle is 120.39 which still falls in the neutral range of C-N-C angle.
ΔpKa of nicotinamide and protocatechuic acid is –0.91 which supports the formation of
neutral bond as explained in case of 2.
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Table 2.5: C-N-C angles in neutral nicotinamide cocrystals from CSD

FIFLAI

C-N-C angle
(0)
117.98

IACNCA
JEMDIP

Refcode

PEQBES

C-N-C angle
Refcode
(0)
118.00
XAQQIQ

117.44

UCOTUC

116.81

117.05

XAQPUB

117.47

Refcode

JILZOU

C-N-C angle
(0)
117.39
118.25
118.42

Figure 2.26: Overall packing of 6
The majors peaks at 8.4, 11.5, 16.7and 19.2 o from the experimental PXRD data
matches with the calculated PXRD pattern (Figure 2.16a). DSC shows the sharp
endotherm at 2000C (Figure 2.16b)which falls in between the melting points of starting
material (PA: 2050C and nicotinamide: 128-1310C).

Figure 2.27: Chain of disordered PA and water molecules hydrogen bonding with
carbamazepine dimers
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In single crystal analysis of dihydrate of PA, carbamazepine cocrystal; PA is not
very well defined in the structure. The reason can be disorder or twinning in the crystal.
Model of the disorder shows that PA forms chins with water molecules and hydrogen
bonded to carbamazepine dimers. R factor is approximately 5% so model can be reliable.
Structure can solved in lower space group but can not be refined very well.

2.3 Dissolution Studies
To address solubility, dissolution and other physicochemical properties;
cocrystals have come up with a promising future as explained in section 1.2.4. Having
understood the importance of it, the efforts are underway to correlate the solubility and
stability of a cocrystal with properties of pure components and if one can predict the
trend in solubility. To concentrate on this issue Rodrı´guez-Hornedo et.al has recently
published the study of 25 cocrystals of carbamazepine with their dissolution data and
they have concluded that (1) solubility increases with the solubility of cocrystal
components, (2) ligand transition concentrations increase with cocrystal and ligand
solubilities for cocrystals of the same drug, and (3) ligand solubility about 10-fold higher
than drug leads to cocrystal being more soluble than drug.15
For further contribution to this regard dissolution studies of cocrystals of PA have
been carried out. In formulating and controlling the drug quality, dissolution is commonly
used technique in pharmaceutical industries. 16 The common analytical methods used for
the quantification in dissolution studies are mainly spectrophotometric, chromatographic,
mass spectrometric and potentiometric. 17 UV/VIS spectrophotometry is the most
prominent method. Cocrystals 1, 2 and 5,6 are chosen for the dissolution studies. Water
solutions of all cocrystals show absorption band in UV/VIS. The dissolution studies are
carried out with respect to PA and 310 nm was chosen to be the common wavelength for
all cocrystals where absorption of cocrystal formers does not interfere with the absorption
of PA. As kinetic dissolution is influenced by particle size distribution and experimental
apparatus, all the cocrystals were sieved using ASTM standard sieve to obtain particle
sizes between 53-75 m. All the experiments were carried out at room temperature and in
set of three for the reliability under constant and same stirring speed. Calibration curves
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are determined in set of three with seven varying dilutions. Approximately 80-100 ml of
water was used and an aliquot was drawn from the resulting slurry of cocrystal at regular
time intervals using a syringe. The filtrate (use of 0.25 m nylon filter) was diluted with
water and UV absorption was recorded. Results are plotted as concentration (mg/ml)
versus time (min) and are summarized in figure 2.28.
It has been observed that apart from cocrystal 1 all other cocrystals 2, 4, and 5
lower the solubility of PA. The solubility of cocrystal formers is in the order of
caprolactam > nicotinamide > isonicotinamide > theophylline. Solubility of theophylline
is less than the pure PA and all others are having higher solubility than PA. It was
observed based on Rodrı´guez-Hornedo et.al. studies15 as the solubility of cocrystal
former increases the solubility of cocrystal increases and thus cocrystals 1,2 and 6 should
increase PA solubility and 5 should decrease the solubility of PA. As predicted 1 showed
an increase in solubility of PA about one and half fold and 5 showed about four fold
decrease in solubility of PA. But 2 and 6 are the outliners. As per the assumption as
isonicotinamide and nicotinamide are more soluble cocrystal formers and furthermore
nicotinamide has higher solubility than isonicotinamide, 6 predicted to be higher in
dissolution profile than 2 and PA. The observed data is contradictory to the assumptions
and thus cocrystals afford solubility in unpredictable manner.
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Figure 2.28: Comparison of dissolution profiles of PA and its cocrystals
To correlate dissolution profiles the detail comparison of crystal packing was
carried out. As shown in figure 2.16 and 2.20 acid-acid dimer of PA is intact while in
case of 2 and 6 as shown in figures 2.17 and 2.22 acid dimer is interrupted and acidpyridine and acid-amide supramolecular heterosynthons are observed respectively.
Furthermore isonicotinamide and nicotinamide cocrystals show pi stacking (Figure 2.29)
that may be increasing the lattice energy causing lower solubility. Pi stacking is stronger
in 6 than 2.
Another observation is, as solubility decreases melting point of cocrystal
increases. Melting temperatures of pharmaceutical crystals have been found an important
indicator in solubility prediction. In structurally similar pharmaceutical crystalline drugs,
high melting drugs are generally recognized to possess lower solubility.18 Even though it
is generally expected that solubility and melting points are correlated it has not been
observed in case of study of carbamazepine cocrystals.15
Dissolution profiles of cocrystals also suggest the thermodynamic stability of the
cocrystals. In conclusion PA as a small molecule has altered the solubility of its
cocrystals with caprolactam, isonicotinamide, nicotinamide and thophylline. The trend of
the solubility is independent of the solubility of a cocrystal former in case of PA since
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direct proportionality was not observed. But it correlates with melting temperature of a
cocrystal and higher temperature lowers the solubility.

(a)

(b)

Figure 2.29: Pi stacking in (a) PA nicotinamide (b) PA isonicotinamide cocrystals
In conclusion, seven novel cocrystals of PA have been developed using the
strategies of crystal engineering. The OH…OH supramolecular homosynthon has been
defeated by supramolecular heterosynthon in all cocrystals. As per the CSD statistics
phenol…pyridine supramolecular heterosynthon is more reliable than phenol…phenol
supramolecular homosynthon and it has been seen in cocrystals of PA-nicotinamide. But
in case of cocrystals of PA with isonicotinamide and isonicotinic acid...pyrine
supramolecular heterosynthon overcomes the phenol…pyridine supramolecular
homosynthon as reported in case of competition of supramolecular synthons when both
COOH and OH moieties are present with aromatic nitrogen base.11 In isonicotinamide,
isonicotinic acid and nicotinamide molecules aromatic nitrogen acts as a free base and
accepts hydrogen from phenol or acid moiety. Theophylline has a tendency to form dimer
leaving carbonyl as hydrogen accepter which has been also observed in case of PAtheophylline cocrystal. Furthermore dissolution studies of cocrystals shows an alteration
in solubility of PA with the formation of cocrystal. The solubility of a cocrystal is
irrespective of the solubility of the cocrystal former.
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3. Quercetin
3.1 Introduction

Figure 3.1: Structure of Quercetin
Flavonoids are a group of phenolic plant compounds which are secondary
metabolites of plant.1 To date, more than 6000 flavonoids have been identified.2 They are
present in most edible fruits and vegetables, but the type of flavonoids obtained from
different dietary sources varies. 3 Flavonoids and flavonoid containing products have
been reported to possess biological activities.4 Flavonoids are divided into several
subgroups. They consist of 2 benzene rings (A and B), which are connected by an oxygen
containing pyrene ring (C). Flavonoids containing a hydroxyl group in position C-3 of the
C ring are classified as 3-hydroxyflavonoids e.g. flavonols and those lacking it as 3deoxyflavonoids e.g. flavanones and flavones.
Quercetin (3,4,7,3‟,4‟-pentahydroxyflavanone, C15H10O7, Mol.Wt. 302.326,
M.P.3160C) is one of the most prevalent flavonol present in health food. Several studies
have been carried out on the daily intake of quercetin in different countries and the
importance of different foods in quercetin sources. Hertog et. al. concluded that wine was
the major source of quercetin in Italy, while onion and apples contributed most in the
United States, Finland, Greece, and former Yugoslavia.5 Recently Hakkinen et. al.
estimated that onions, followed by tea, apples, and berries are the major sources of
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quercetin in Finland. Besides its antioxidative and anticancer properties, quercetin also
has been reported to benefit prostatitis and interstitial cystitis 6, 7. Thus quercetin can be
viewed as a promising pharmacological agent because of the popular usage of products
containing quercetin. According to BCS classification quercetin is a low soluble (0.45g/l)
molecule. The bioavailability of quercetin is 5.3% in rats and LD50 is 163 mg/kg.8 This
low solubility and bioavailability limits the usage of quercetin. As explained in section
1.2.4; cocrlystallization can alter the solubility and bioavailability of the target molecule.
The study herein focuses to synthesize cocrystals of quercetin to improve its solubility
and thus bioavailability.
Quercetin contains four phenolic OH groups and one hydroxyl group which can
act acceptor/donor and one carbonyl and one ether moiety which can act as a hydrogen
bond acceptor. Based on the CSD search as discussed in section 1. 4.2 for the occurrence
of supramolecular synthons between polyphenols and other functionalities, aromatic
nitrogen, carbonyls and amides would be promising. Thus different cocrystal formers
were selected on the basis of their solubility, toxicity, pKa and cost as summarized in
tables 1. 3, 1.4 and 1.5.

3.1.1 Quercetin in CSD
To date, the crystal structure of pure quercetin is not known but CSD contains two
entries for quercetin dihydrate (Ref. codes: FEFBEX, FEFBEX01).
In the crystal packing of quercetin dihydrate quercetin exists as dimer through
phenolic OH…carbonyl sypramolecular heterosynthon. These two functionalities form
intermolecular hydrogen bonding too within the quercetin molecule. This quercetin
dimers are hydrogen bonded to other dimers through water molecule. This extended
hydrogen bonding network forms a sheet structure.
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Figure 3.2: OH…carbonyl supramolecular heterosynthon in quercetin dihydrate

Figure 3.3: Intermolecular interactions in the 1:1:1 cocrystal solvate of quercetin,
caffeine and methanol
Apart from the CSD entries, Zaworotko et.al patented three cocrystals of
quercetin; 1:1:1 cocrystal of quercetin, caffeine and methanol, 1:1 cocrystal of quercetin
and isonicotinamide and de-solvated cocrystal of quercetin and caffeine.9 The single
crystal analysis for de-solvated cocrystal of quercetin-caffeine is not available. The
crystal structure of cocrystal of methanol solvate of quercetin and caffeine shows that
caffeine interacts with quercetin molecule through phenolic OH…Narom (2.831 Ao) and
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OH…O=C (2.716 Ao) supramolecular heterosynthon. Another carbonyl of caffeine
molecule hydrogen bonds to methanol molecule (OH…O: 2.712 Å). Quercetin molecules
hydrogen bonds with each other via OH…OH (2.774 Å, 2.847 Å) supramolecular
homosynthon. Overall it forms stacked sheets.
The crystal structure of quercetin and isonicotinamide shows that quercetin and
isonicotinamide forms a four component assembly composed of two phenolic OH…O=C
(from isonicotinamide) (2.607 Å) supramolecular heterosynthon and two NH…OH (3.028
Å) supramolecular heterosynthons. Quercetin molecule forms a dimer with OH…OH
(2.765 Å) supramolecular homosynthon.

Figure 3.4: Intermolecular interactions in the 1:1 Quercetin-Isonicotinamide
cocrystal

3.2 Cocrystals of quercetin
Two novel cocrystals of quercetin with isonicotinic acid and theobromine were
prepared. As discussed in 3.1 phenolic OH groups and carbonyl group were utilized to
form a cocrystal with the functional groups from isonicotinic acid and theobromine. The
summary of cocrystals synthesized is listed in table 3.1.

3.2.1 Experimental Section
All the chemicals were obtained from commercial sources and used without
further purification. Solvents were also purchased from commercial sources and distilled
before use. The single crystals of cocrystals 1 and 2 were obtained by slow evaporation of
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stoichiometric amounts of starting materials in an appropriate solvent as summarized in
table 3.2, and they were removed from their mother liquors before complete evaporation
of the solvent had occurred. All samples were characterized by powder X-ray diffraction,
infrared spectroscopy, differential scanning calorimetry, thermogravimetric analysis and
single crystal X-ray diffraction.
Table 3.1: Summary of cocrystals of quercetin obtained
Cocrystal

Target molecule

1

Isonicotinic acid

2

Theobromine

Structure
and Ratio
Monohydrate
(1:1:1)
Dihydrate
(1:1:2)

Melting Point
(0C)

Yield
(%)

283

95.5

294

65.9

3.2.2 Cocrystallization via Solution Crystallization
1:1:1 cocrystal of quercetin, isonicotinic acid and water 1:
OH
OH
O
HO

OH

O

Acetone + Methanol
C15H10O7.
C6H6NO2.H2O

.2H2O
OH
N
OH

O

Figure 3.5: Synthesis and single crystal of 1
Quercetin dihydrate (33.8 mg, 0.0999 mmol) was dissolved in 10ml of acetone
and isonicotinic acid (12.3 mg, 0.0999 mmol) was dissolved in 2mL of water by heating
on a hotplate. The resulting solutions were filtered together and placed in a refrigerator to
slowly evaporate. After 8 days yellow plate crystals of 1 (26.4mg, 0.0595 mmol, 95.5%)
were obtained and exhibited a melting point of 2830C.
1:1:2 cocrystal of quercetin, theobromine and water 2:
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OH

HO

O

O

CH3
N

N

Ethanol+ Water

OH

2H2O
OH
OH

O

N

N
CH3

O

C5H10O7.C7H8N4O2.2H2O

Figure 3.6: Synthesis and single crystal of 2
Quercetin dihydrate (33.8 mg, 0.0999 mmol) and theobromine (18.0 mg, 0.
0999mmol) were dissolved in 5 ml of ethanol and 10ml of 1:1 mixture of water and
ethanol respectively by heating. Resulting solutions were filtered together and placed in
the refrigerator for slow evaporation. The crystals of 2 (18.2mg, 0.0351mmole, 65.9%)
were harvested after 4 days and exhibited a melting point of 2940C.

3.2.3 Cocrystallization via Grinding and Slurry conversion
Using different methodologies attempts were made to synthesize the cocrystal as
described in section 1.2.6. Only cocrystal 2 was successfully obtained by grinding as well
as slurry conversion.
Table 3.2: Comparison of solvent evaporation, grinding and slurry techniques
Cocrystal
1
2

Molar ratio
used
1:1
1:1

Crystallization
solvent
MeOH/Water
EtOH/Water

Solvent for
grinding
Ethanol

Solvent for
slurry
Ethanol

3.2.4 FTIR, PXRD, Differential Scanning Calorimetry and
Thermo Gravimetric Analysis
All samples were characterized by IR spectroscopy using a Nicolet-Avatar Smart
Miracle 320 FT-IR instrument. The bulk samples were analyzed by X-ray powder
diffraction. PXRD analysis was performed using a Bruker D8 ADVANCE, θ /2 θ
difractometer. Experimental conditions: Cu K radiation (λ= 1.54056 Å); 50 kV and 40
mA. Scanning interval: 3-400 2 θ; time per step: 0.5 s; step size: 0.020. Thermal analysis
was carried out using a TA instruments DSC 2920 differential scanning calorimeter.
Aluminum pans were used for the experiment for all the samples. Temperature
73

calibrations were made using indium as the standard. An empty pan, sealed in the same
way as the sample, was used as a reference. The thermograms were run at a scanning of
100C/ min from 300C to the required temperature on 1-3mg of the sample. Results are
summarized in figures 3.7 and 3.8.
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Figure 3.7: Cocrystal 1: (a) PXRD comparison (b) TGA (c) DSC (d) IR
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Figure 3.8: Cocrystal 2: (a) PXRD comparison (b) TGA (c) DSC (d) IR

3.2.5 Determination of Crystal Structure
Single crystals of cocrystals 1 and 2 were examined under a microscope and
single crystal X-ray diffraction data were collected on a Bruker-AXS SMART APEX
CCD diffractometer with monochromatized Mo K radiation (λ = 0.71073 Å) connected
to a KRYO-FLEX low temperature device.
Table 3.3: Crystallographic data for cocrystals of quercetin
Cocrystal 1

Cocrystal 2

Formula

C21 H17 N O10

C22 H22N4O11

MW

443.36

518.44

Crystal System

Monoclinic

Triclinic

Space group
a (Å)

C2/c

P-1

34.7256(4) Å

7.0110(4)

b (Å)

7.43960(10) Å

11.2992(5)

c (Å)

14.3727(2)

14.9618(7)

(deg)

90°

106.548(3)

(deg)

90.07°

101.816(3)

(deg)

90°

94.797(3)

V /(Å3)

3713.11(8)

1099.29(9)

Dc/ mgcm-3

1.586

1.566

Z

8

2

Z‟

1

1

2 range

2.54 to 67.41

3.17 to 67.25

Nref./Npara.

3207 / 357

3641 / 422

T /K

100(2)

293(2)

R1 [I>2sigma(I)]
wR2

0.0369

0.0430

0.0896

0.1039

GOF

1.047

1.028

Abs coef./mm-1

1.102

1.097
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3.2.6 Results and Discussion

Figure 3.9: Quercetin dimers hydrogen bonding with isonicotinic acid molecules
through phenol…carboxylate supramolcular heterosynthon
The single crystal X-ray analysis of 1 reveals that quercetin molecules form
dimers through hydroxyl-carbonyl (OH…O=C) supramolecular homosynthon. Phenolic
OHb moiety forms an intermolecular hydrogen bond with the carbonyl functionality.
Phenolic OHe is hydrogen bonding to water molecule. And remaining two phenolic OH
groups from ring A and ring B are engaged in hydrogen bonding with one molecule of
isonicotinic acid which are in zwiterionic forms and one molecule of water. Thus each
quercetin molecule is hydrogen bonded to three molecules of water, one molecule of
quercetin and two molecules of isonicotinic acid (Figure 3.9). Isonicotinic acid forms a
chain with expected acid-pyridine supramolecular heterosynthon (Figure 3.10). As
expected from the CSD statistics explained in 1.4.2 acid-pyridine supramolecular
heterosynthon was observed and quercetin dimer is intact.
As explained in section 2.2.6 for cocrystal 3 (cocrystal of PA with isonicotinic
acid), examination of C-N-C angle and location of a proton will distinguish 1 from a
neutral cocrystal or a salt or a zwitreionic cocrystal. The C-N-C angle of 121.700 suggests
the non existence of neutral isonicotinic acid molecule in comparison with the C-N-C
angle is neutral isonicotinic acid molecule (118.910). The location of the proton can be
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confirmed by the C…O distances in carboxylate and in carboxylic acid. In 1, examination
of these bond lengths resulted in the presence of carboxylate ion (C…O: 1.244 Å and
1.263 Å) where as in case of neutral isonicotinic acid molecule these distances are 1.215
Å and 1.294 Å. Furthermore both the formal charges are present on the same molecule
resulting a overall neutral species. Thus 1 is zwiterionic cocrystal and not a salt.

Figure 3.10: Formation of a chain of isonicotinic acid molecules with acidpyridin supramolecular heterosynthon
The major peaks at 5.1, 10.3, 12.2, 13.3, 15.3, 20.5, 24.4 and 30.8o from the
experimental powder x-ray diffraction pattern (Figure 3.7 a) matches with the calculated
powder pattern. DSC shows three endotherms (Figure 3.7 c). The endotherm at 196.170C
corresponds to solvent molecule which is a water molecule and endotherm at 282.680C is
corresponding to cocrystal of anhydrate. The third endotherm around 3200C may be
corresponding to the decomposition of isonicotinic acid and quercetin as well. TGA
(Figure 3.7 b) supports the loss of water molecule (4.85%) which correlates the
calculated % loss (4.05%).
Attempts to dehydrate 1 by heating in vacuum oven were carried out. DSC
showed disappearance of the endotherms at 1960C and 2830C but the endotherm of
decomposition temperature of quercetin and isonicotinic acid was present. Cocrystal
components might be falling apart from each other and decomposing individually.
80

Figure 3.11: DSC after heating cocrystal 1

Figure 3.12: Quercetin dimer hydrogen bonding with one theobromine molecule
through carbonyl-phenol supramolecular heterosynthon
The single crystal X-ray crystallographic study analysis of 2 reveals that quercetin
molecules exist as a dimer through hydroxyl-carbonyl [OH…O: 2.616(2) A0]
supramolecular homosynthon. These dimers are further hydrogen bonding to
theobromine dimers [CO…HN: 1.916 A0] via phenol-carbonyl (OH…O: 2.752(2)A0)
supramolecular heterosynthon from one side and through water molecule from other side.
The remaining phenolic group is hydrogen bonded to Narom of theobromine through water
molecule (OH…OH: 2.796 A0 and H2O…Narom:2.822(3) A0]. Overall it forms a sheet.
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Adjacent sheets are linked to each other through water molecule to give an overall 3D
network (Figure 3.13).

Figure 3.13: Formation of sheet structure in 2
Theobromine is a molecule from xanthine family and a major constituent of
chocolate. Theobromine is a bitter alkaloid of cacao plant. The name theobromine is
derived from theobroma meaning food of the gods in Greek. The use of theobromine in
cancer has been patented10 and currently theobromine is used as a vasodilator, diuretic
and heart stimulant.11 The crystal structure for pure theobromine is known in CSD (Ref.
code: SEDNAQ). It reveals that theobromine molecules form dimer through amide-amide
supramolecular homosynthon. Apart from the pure structure two cocrystals [Ref. code:
CSATBR (with 5-chlorosalicylic acid) and HIJYEF (malonic acid)] are known. In both
the cocrystals it can be observed that theobromine forms acid… amide dimer and
imidazolyl nitrogen acts as a hydrogen bond acceptor and forms supramolecular synthon
with respective carboxylic acid OH moiety.
In case of 2 theobromine amide dimer is observed and imidazolyl nitrogen acts as
hydrogen acceptor through supramolecular heterosynthon with water molecule. Carbonyl
functionality of theobromine forms supramolecular heterosynthon with phenolic OHa of
quercetin which correlates with CSD statistics explained in 1.4.2. Attempts to synthesize
the anhydrous cocrystal of theobromine were made. The cocrystal was heated in vacuum
oven at 1200C for 3 hours. DSC showed dehydrated product. When PXRD pattern of 2
and dehydrated product was compared it was observed that all the peaks from the 2 were
present but shifted to left in dehydrated product. After 30 min. TGA was recorded and it
was observed that cocrystal contains 1.1% of water. It can be concluded that cocrystal
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might not be stable and during the course of the investigation cocrystal absorbs water
from air giving a hydrated product.
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Figure 3.14: (a) PXRD pattern (b) DSC (C) TGA of attempts of synthesizing
anhydrous cocrystal of 2

3.3 Dissolution Studies
Low solubility and bioavailability limits the use of quercetin as a therapeutic
target molecule. The dissolution studies of cocrystals of quercetin with isonicotinamide
and caffeine methanol solvate are already patented and it has been shown the six fold
increase in solubility of quercetin in both the cases.9 Furthermore de-solvated cocrystal of
quercetin-caffeine shows 21 fold increase. Also in case PA molecule; as explained in
section 4.3; the direct proportionality to the solubility of cocrystal former was not
observed. Thus dissolution study was carried out with 2. Attempts to study cocrystal 1
were unsuccessful. The scaling up of the product was attempted which resulted in the
precipitation of isonicotinic acid with the cocrystal.
As explained in section 2.3, UV/VIS was used to carry out dissolution
experiment. As quercetin did not show any absorbance in water, a suitable solvent in
which the cocrystal is soluble and shows absorption was found.
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The first choice of the solvent was 1:1 ethanol/water (V/V%) since previous
studies were carried out in the same solvent system. The standard calibration curve was
plotted by preparing standard solution of a cocrystal in EtOH/water system. The bulk
powder of a cocrystal was sieved in order to get the particle size between 53-75 m using
ASTM standard sieves. Experiment was carried out in set of three using 80 ml of the
solvent and 800 mg of cocrystal. The resulting slurry was stirred for four hours and at
regular intervals of time an aliquot was drawn, filtered through 0.25 m nylon filter,
diluted with appropriate amount of same solvent system and UV absorption was
recorded. The result is plotted as concentration (mg/ml) Verses time (min) (Figure 3.15).
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Quercetin dihydrate; hydroxyl-carbonl
Rel.Sol.1; mp=316 degreeC
1:1:2 theobromine, water; hydroxyl-carbonyl
dimer intact; Rel.Sol. 0.7; mp=294 degree C
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Figure 3.15: Dissolution profiles of dihydrate of 1:1 cocrystal of quercetin
and theobromine, in 1:1 EtOH/Water (V/V%) system at 360 nm
It can be viewed from the plot that the solubility of the cocrystal maximizes
within first five minutes and then slowly goes down to that of quercetin dihydrate. But
the solubility of the quercetin has been improved by approximately 1.5 fold. Even though
it is not a significant change it can be concluded that solubility of cocrystal is
independent of the solubility of cocrystal former.
In conclusion two novel cocrystals of quercetin have been developed using crystal
engineering strategies. As expected from CSD statistics in case of 1, acid…pyridine
supramolecular heterosynthon has been observed. Observed quercetin dimer in quercetin
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dihydrate and cocrystal of quercetin isonicotinamide is also present in both cocrystals (1
and 2).The tendency of theobromine forming dimer leaving carbonyl moiety as hydrogen
acceptor is also observed. Anhydrous cocrystals of 1 and 2 are found to be unstable.
Dissolution study of 2 shows increase in solubility of quercetin dihyrate and similarly as
discussed in case of PA, direct proportionality between solubility of cocrystal former and
solubility of cocrystal is not observed.
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4. CONCLUSION AND FUTURE DIRECTIONS
Development of crystal engineering has led the foundation for supramolecular
chemistry. The importance of supramolecular chemistry has been established by a vast
array of applications. Discovery of new forms of drugs such as hydrates, solvates,
polymorphs and cocrystals are overcoming the problems associated with drugs such as
stability, solubility and bioavailability. Cocrystals have proved their importance in this
regards and attracting pharmaceutical industries vastly. Using the strategies of crystal
engineering the work herein has led to develop novel cocrystals of protocatechuic acid
and quercetin with pharamaceutically accepted molecules (cocrystal formers) such as
caprolactam, isonicotinamide, isonicotinic acid, theophylline, nicotinamide and
theobromine. Cocrystals are synthesized and structurally characterized. Cocrystals of
protocatechuic acid establish its use as cocrystal former.
Furthermore the effect of these cocrystals has been studied in regards with the
solubility of pure protocatechuic acid and quercetin. Dissolution studies of protocatechuic
acid have been carried out to study the trends in the solubility of cocrystals with respect
to a cocrystal former. The predicted direct proportionality has not been observed. But the
trend in the melting point of a cocrystal and its solubility has been observed. As the
melting point of a cocrystal increases the solubility decreases. Thus crystal packing of a
cocrystal influences its solubility. The study herein contributes in the limited literature
available regarding to the predictability of cocrystal solubility. Attempts to improve
solubility of quercetin via cocrystallization were achieved. Quercetin theobromine
dihydrate cocrystal results in 1.5 fold increase in solubility of quercetin. As observed in
case of protocatechuic acid, direct relationship between solubility of quercetin and
theobromine is not observed. Thus evaluation of physicochemical properties of
pharmaceutical cocrystals and its predictability is an important area for additional
research. The results reported herein could be the subject of future contributions.
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